Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death
Cells · 2024
DOI: 10.3390/cells13050388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Elena V Sazonova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Swedish Cancer Society, Radium Hemmets Research Funds.
Abstract (Originalsprache)
The development of resistance to chemotherapy is one of the main problems for effective cancer treatment. Drug resistance may result from disturbances in two important physiological processes—cell proliferation and cell death. Importantly, both processes characterize alterations in cell metabolism, the level of which is often measured using MTT/MTS assays. To examine resistance to chemotherapy, different cancer cell lines are usually used for the in vitro modulation of developing resistance. However, after the creation of resistant cell lines, researchers often have difficulty in starting investigations of the mechanisms of insensitivity. In the first stage, researchers should address the question of whether the drug resistance results from a depression of cell proliferation or an inhibition of cell death. To simplify the choice of research strategy, we have suggested a combination of different approaches which reveal the actual mechanism. This combination includes rapid and high-throughput methods such as the MTS test, the LIVE/DEAD assay, real-time cell metabolic analysis, and Western blotting. To create chemoresistant tumor cells, we used four different cancer cell lines of various origins and utilized the most clinically relevant pulse-selection approach. Applying a set of methodological approaches, we demonstrated that three of them were more capable of modulating proliferation to avoid the cytostatic effects of anti-cancer drugs. At the same time, one of the studied cell lines developed resistance to cell death, overcoming the cytotoxic action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
- Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.
- Division of Toxicology, Institute of Environmental Medicine, Karolinska Institute, P.O. Box 210, 17177 Stockholm, Sweden.
ORCID-Profile: Boris Zhivotovsky
Förderung
- Russian Science Foundation
- Swedish Cancer Society
- Radium Hemmets Research Funds
- Swedish
- Stockholm
Zitieren
APA
Sazonova, E. V., Yapryntseva, M. A., Pervushin, N. V., Tsvetcov, R. I., Zhivotovsky, B., & Kopeina, G. S. (2024). Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death. Cells. https://doi.org/10.3390/cells13050388
Vancouver
Sazonova EV, Yapryntseva MA, Pervushin NV, Tsvetcov RI, Zhivotovsky B, Kopeina GS. Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death. Cells. 2024. doi:10.3390/cells13050388
BibTeX
@article{Sazonova2024,
author = {Sazonova, Elena V and Yapryntseva, Maria A and Pervushin, Nikolay V and Tsvetcov, Roman I and Zhivotovsky, Boris and Kopeina, Gelina S},
title = {Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13050388}
}
EUVIMED